FYI, pasted ...ARNA should be all over this!
ASCO called for increased education, research and advocacy to reduce the toll of obesity, both as a leading cause of cancer and a complication in the care of cancer patients. ASCO recommendations outline four critical priorities, including increased education and awareness about links between obesity and cancer; development of new physician tools and resources; intensified and highly coordinated research; and policy changes to increase access to obesity screening, diagnosis and treatment. The statement was published online on October 1, 2014 in the Journal of Clinical Oncology
Thanks again S9, you are the best! BTW, any thoughts on ACAD?
From the recent filing. I urge all IMGN shareholders that want change to take the time to let the money-sucking, do-nothing BOD know your opinion.
Can I communicate with ImmunoGen's directors?
Yes. Shareholders who wish to communicate with the Board or with a particular director may send a letter to ImmunoGen, Inc., 830 Winter Street, Waltham, MA 02451, attention: General Counsel. The mailing envelope should contain a clear notation that the enclosed letter is a "Shareholder-Board Communication" or "Shareholder-Director Communication." All such letters should clearly state whether the intended recipients are all members of the Board or certain specified individual directors. The general counsel will make copies of all such letters and circulate them to the appropriate director or directors.
It's the IMGN shareholders that are suffering a financial hardship. Are you kidding me? Unless the major shareholders ban together and replace the BOD, shareholders are sunk. We need to get in touch with the major shareholders and get them to vote the BOD out as a first step.
We also need someone to go to Boston and represent the retail shareholders. IMGN needs change urgently.
Better hire another local reporter to try and improve your image. Reality is, so far you're a failed leader destroying shareholders value. IMGN has great technology and is failing to deliver value, products, ROI. BOD is complicit in your failure. Burn rate is increasing, clock is ticking...You all need to be replaced!
Spreading garbage. ZFGN's obesity drug is a joke, a commercial failure waiting to happen IMO.
you can't beat them unless you are a FT trader and trade against the exaggerated moves. Have to sell high to buy low, etc. Otherwise, buy and hope, or buy stock and puts for protection, or buy in the money calls to limit risk, or buy a call spread.
I figured as much. At first glance the new Perjeta numbers looked impressive, but when you look at the Roche presentation info referenced below, it's clear to me that Roche is expecting the final best combo to be Perjeta and Kadcyla. The issue with that combo will be cost, assuming Kad adds to both safety and efficacy vs. Herceptin and not just PFS, but OS. The next issue to settle is which is better alone, P or K, or is there a bio-marker to predict in which patients one will will work better than the other. I am sure Roche is figuring this all out for patients and for their bottom line.
thanks, yes I decided to stop being lazy and read the article, very interesting. One day they will arrest him and some of his hedge fund partners in crime IMO.
did the article name AF and provide any facts? I have seen this mentioned on other boards. Short criminals are all over this industry, would love to see them exposed and prosecuted finally.
it's not going to $18 again, it's either going up big if/after acquisition, flat to up after approval, or down big if something bad happens. Hoping an acquisition removes the risk and any decision-making.
When retail investors start bragging about how much they made in a stock it's a reliable sell signal and magnet to short sellers. Unless/until either the company is acquired, or Pima is approved and the stock goes up, or you sell, I would not start celebrating.
The future for Her+ patients is Kad + Perj. Kad is clearly more safe and effective than Herceptin. There's no study adding both Herceptin and Kad with Perj, that would be toxic and redundant.
Thanks for your contributions CH. I think ARNA is starting to turn the corner, you might want to keep an eye on them. Only problem is similar to IMGN, weak CEO.
I think you posters have overly high expectations. If insiders are selling stock in the $20's do you really think the company is worth $50, 75, $100 right now? If they get an offer soon it's likely to be under $50. If they show efficacy in Alzheimer's, then the price will sky rocket, but that's at least 1-2 years out. Prior to PDP approval and a successful launch, the current stock price is pretty fair/fully valued. Maybe we get up to $30 before an offer or approval, but not much higher until a successful launch is verified. IMO of course.
Good relative and good to grow off the large number last week, but I was hoping for more considering the extra advertising and Bel-Phen info...
most of their long holdings in biotech are also heavily shorted. I would think they would have to list that (shorts against longs) as a sale for tax and reporting purposes. Maybe they "invest" in another firm that does the shorting to avoid this?